Skip to content

Prospective, single-center study on the efficacy and safety of Contezolid tablets in the treatment of Gram-positive pulmonary infection

Prospective, single-center study on the efficacy and safety of Contezolid tablets in the treatment of Gram-positive pulmonary infection

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093212
Enrollment
Unknown
Registered
2024-11-29
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-positive pulmonary infection

Interventions

contezolid group:contezolid tablets for Gram-positive pulmonary infection

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Patients with lung infection caused by gram-positive bacteria; 3. According to the European Society of Critical Care Medicine (ESICM) definition of acute gastrointestinal injury (AGI) and the severity of the four-level scale, gastrointestinal function is judged as grade I and grade II patients;

Exclusion criteria

Exclusion criteria: 1. People who are allergic to oxazolidinones or have severe allergies; 2. Pregnant and lactating women; 3. It is not suitable for oral/nasal feeding/gastrointestinal nutrition tube administration, or there are gastrointestinal diseases that will seriously affect oral drug absorption; 4. Participants in other clinical trials; 5. Clinical trial participants deemed unsuitable by the investigator;

Design outcomes

Primary

MeasureTime frame
efficacy;

Secondary

MeasureTime frame
safety;

Countries

China

Contacts

Public ContactLi Yang

The First Affiliated Hospital of Xi'an Jiaotong University

doc_liyang@126.com+86 15829760158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026